Room temperature stable oral calcitonin formulation
Room-temperature stable dosage forms for oral delivery of calcitonin are disclosed herein. Dosage forms for oral delivery of calcitonin with low water content are also disclosed herein. Further disclosed herein are methods for producing such room-temperature stable dosage forms and low-water content dosage forms. Methods of treatment comprising the administration of such room-temperature stable dosage forms and low-water content dosage forms are also disclosed herein.
1. A method for preparing a tablet for oral delivery of calcitonin comprising:
(a) dry blending calcitonin, silicified microcrystalline cellulose, coated citric acid, copovidone, crospovidone, and magnesium stearate;
(b) compressing the blended mixture into a tablet core;
(c) applying a water-soluble barrier layer in an initial spray at a first spray rate sufficient to add approximately 0.25% (w/w) to the tablet core in about 30 minutes at an average product temperature of at least 45° C.; and
(d) applying an enteric coating.
2. A method for spray coating a tablet core for oral delivery of calcitonin comprising:
(a) providing a tablet core;
(b) applying a water-soluble barrier layer in an initial spray at a first spray rate sufficient to add approximately 0.25% (w/w) of the water-soluble barrier layer to the tablet core in about 30 minutes at an average product temperature of at least 45° C.; and
(c) applying an enteric coating.
3. The method of claim 2 , wherein the tablet core comprises
(a) calcitonin intermixed with coated citric acid particles,
(b) crospovidone;
(c) copovidone;
(d) microcrystalline cellulose; and
(e) magnesium stearate.
4. The method of claim 3 , wherein the microcrystalline cellulose is silicified microcrystalline cellulose.
5. The method of claim 1 , wherein the tablet core comprises
(a) about 0.01% (w/w) to about 0.10% (w/w) salmon calcitonin;
(b) about 62% (w/w) maltodextrin-coated citric acid;
(c) about 1.1% (w/w) crospovidone;
(d) about 5% (w/w) copovidone;
(e) about 31% (w/w) silicified microcrystalline cellulose; and
(f) about 0.5% (w/w) magnesium stearate.
6. The method of claim 5 , wherein the tablet core comprises about 0.02% (w/w) salmon calcitonin.
7. The method of claim 1 , wherein the first spray rate is sufficient to add approximately 0.5% (w/w) of the water-soluble barrier layer to the tablet core in about 30 minutes.
8. The method of claim 1 , wherein after applying the water-soluble barrier layer at the first spray rate for at least 30 minutes, the water-soluble barrier layer is applied in a subsequent spray at a second spray rate, which is faster than the first spray rate.
9. The method of claim 8 , wherein the second spray rate is sufficient to add about 5.5% (w/w) of the water-soluble barrier layer to the tablet core in about two hours to about four and a half hours.
10. The method of claim 8 , wherein the method comprises applying the water-soluble barrier layer at the first spray rate until about 0.5% (w/w) to about 2.0% (w/w) of the water-soluble barrier layer is added to the tablet core and then applying the water-soluble barrier layer at the second spray rate.
11. The method of claim 10 , wherein the water-soluble barrier layer is applied at the second spray rate until a total of about 3.0% (w/w) to about 7.0% (w/w) of the water-soluble barrier layer is added to the tablet core.
12. The method of claim 2 , wherein the average product temperature during the initial spray is at least 46° C. to at least 50° C.
13. The method of claim 1 , wherein the minimum product temperature during the initial spray is at least 45° C.
14. The method of claim 1 , wherein the enteric coating adds about 6% to about 8% to the weight of the tablet, including the tablet core and the water-soluble barrier layer.
15. The method of claim 2 , wherein after applying the water-soluble barrier layer at the first spray rate for at least 30 minutes, the water-soluble barrier layer is applied in a subsequent spray at a second spray rate, which is faster than the first spray rate.
16. The method of claim 15 , wherein the second spray rate is sufficient to add about 5.5% (w/w) of the water-soluble barrier layer to the tablet core in about two hours to about four and a half hours.
17. The method of claim 15 , wherein the method comprises applying the water-soluble barrier layer at the first spray rate until about 0.5% (w/w) to about 2.0% (w/w) of the water-soluble barrier layer is added to the tablet core and then applying the water-soluble barrier layer at the second spray rate.
18. The method of claim 17 , wherein the water-soluble barrier layer is applied at the second spray rate until a total of about 3.0% (w/w) to about 7.0% (w/w) of the water-soluble barrier layer is added to the tablet core.
19. The method of claim 2 , wherein the average product temperature during the initial spray is at least 46° C. to at least 50° C.
20. The method of claim 2 , wherein the minimum product temperature during the initial spray is at least 45° C.